AR052926A1 - Forma cristalina gama del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones que la contienen - Google Patents

Forma cristalina gama del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones que la contienen

Info

Publication number
AR052926A1
AR052926A1 ARP060100730A ARP060100730A AR052926A1 AR 052926 A1 AR052926 A1 AR 052926A1 AR P060100730 A ARP060100730 A AR P060100730A AR P060100730 A ARP060100730 A AR P060100730A AR 052926 A1 AR052926 A1 AR 052926A1
Authority
AR
Argentina
Prior art keywords
expressed
crystalline form
degrees
procedure
preparation
Prior art date
Application number
ARP060100730A
Other languages
English (en)
Inventor
Stephane Horvath
Gerard Damien
Marie-Noelle Auguste
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052926(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR052926A1 publication Critical patent/AR052926A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • G—PHYSICS
    • G04—HOROLOGY
    • G04F—TIME-INTERVAL MEASURING
    • G04F1/00—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
    • G04F1/04—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity
    • G04F1/06—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity by flowing-away of a prefixed quantity of fine-granular or liquid materials, e.g. sand-glass, water-clock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/214—Monitoring or handling of messages using selective forwarding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/212—Monitoring or handling of messages using filtering or selective blocking

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forma cristalina gamma del clorhidrato de ivabradina de formula (1), caracterizado porque el siguiente diagrama de difraccion sobre polvo, medido en un difractometro PANlytical X'Pert Pro con un detector X'Celerator, y expresado en términos de posicion de rayo (ángulo de Bragg 2 Theta, expresado en grados), de altura de rayo (expresado en cuentas), de área de rayo (expresada en cuentas por grados), de ancho de rayos a media altura (ôFWHMö, expresada en grados) y de distancia interplanar d (expresada en Angstrom):
ARP060100730A 2005-02-28 2006-02-28 Forma cristalina gama del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones que la contienen AR052926A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501989A FR2882555B1 (fr) 2005-02-28 2005-02-28 Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
AR052926A1 true AR052926A1 (es) 2007-04-11

Family

ID=34954955

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100730A AR052926A1 (es) 2005-02-28 2006-02-28 Forma cristalina gama del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones que la contienen

Country Status (42)

Country Link
US (3) US7361650B2 (es)
EP (1) EP1707562B1 (es)
JP (1) JP4628974B2 (es)
KR (1) KR100835447B1 (es)
CN (1) CN100402502C (es)
AP (1) AP1956A (es)
AR (1) AR052926A1 (es)
AT (1) ATE396974T1 (es)
BR (1) BRPI0600796B8 (es)
CA (1) CA2537400C (es)
CO (1) CO5770097A1 (es)
CR (1) CR8249A (es)
CU (1) CU23616B7 (es)
CY (1) CY1109010T1 (es)
DE (1) DE602006001312D1 (es)
DK (1) DK1707562T3 (es)
EA (1) EA008465B1 (es)
ES (1) ES2308689T3 (es)
FR (1) FR2882555B1 (es)
GE (1) GEP20084467B (es)
GT (1) GT200600088A (es)
HK (1) HK1096659A1 (es)
HR (1) HRP20080406T5 (es)
IL (1) IL173959A0 (es)
JO (1) JO2515B1 (es)
MA (1) MA28134A1 (es)
ME (1) ME02747B (es)
MY (1) MY158129A (es)
NO (1) NO338481B1 (es)
NZ (1) NZ545578A (es)
PE (1) PE20061142A1 (es)
PL (1) PL1707562T3 (es)
PT (1) PT1707562E (es)
RS (1) RS50598B (es)
SA (1) SA06270040B1 (es)
SG (1) SG125229A1 (es)
SI (1) SI1707562T1 (es)
TW (1) TWI314143B (es)
UA (1) UA86595C2 (es)
UY (1) UY29406A1 (es)
WO (1) WO2006092492A1 (es)
ZA (1) ZA200601764B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
ATE544754T1 (de) 2006-11-30 2012-02-15 Cadila Healthcare Ltd Verfahren zur herstellung von ivabradinhydrochlorid
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
JP5632279B2 (ja) 2007-05-30 2014-11-26 アイエヌディー−スイフト ラボラトリーズ リミテッド 塩酸イバブラジンの調製方法及びポリモルフ
CN102264689B (zh) 2008-12-22 2014-12-31 新梅斯托克尔卡公司 制备伊伐布雷定的方法
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
HUE035588T2 (en) 2010-02-12 2018-05-28 Krka D D Novo Mesto Form of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
EP2726462B1 (en) 2011-08-02 2017-03-22 Sandoz AG Acetone solvate of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2780327A1 (en) 2011-11-14 2014-09-24 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
CN103183639B (zh) * 2011-12-30 2015-06-17 浙江京新药业股份有限公司 一种稳定的盐酸伊伐布雷定ii晶型及其制备方法
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
FI2781509T4 (fi) * 2013-03-19 2023-09-07 Ivabradiinihydrokloridin uusi polymorfi ja sen valmistusmenetelmä
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
MX363389B (es) 2013-12-12 2019-03-20 Synthon Bv Composicion farmaceutica que comprende ivabradina amorfa.
SI2774606T1 (sl) 2014-02-14 2019-05-31 Synthon B.V. Farmacevtski sestavek, ki obsega polimorf IV ivabradin hidroklorida
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2017173458A1 (en) * 2016-04-01 2017-10-05 Swiderski Cyprianna Compositions and methods targeting hcn channels for breathing therapeutics
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
WO2020092288A1 (en) 2018-10-30 2020-05-07 Amgen Inc. Process of making ivabradine hydrochloride drug product
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
CR8249A (es) 2008-01-21
ME02747B (me) 2010-05-07
CA2537400C (fr) 2009-12-15
AP1956A (en) 2009-02-18
NZ545578A (en) 2007-02-23
GT200600088A (es) 2006-10-24
BRPI0600796A (pt) 2007-08-14
NO338481B1 (no) 2016-08-22
CA2537400A1 (fr) 2006-08-28
CN100402502C (zh) 2008-07-16
AU2006200857A1 (en) 2010-01-28
TW200640872A (en) 2006-12-01
CU23616B7 (es) 2011-01-27
TWI314143B (en) 2009-09-01
BRPI0600796B1 (pt) 2019-02-19
ZA200601764B (en) 2007-05-30
MA28134A1 (fr) 2006-09-01
BRPI0600796B8 (pt) 2021-05-25
US7867996B2 (en) 2011-01-11
US20060194963A1 (en) 2006-08-31
WO2006092492A1 (fr) 2006-09-08
CN1827602A (zh) 2006-09-06
JP2006241156A (ja) 2006-09-14
EA008465B1 (ru) 2007-06-29
JP4628974B2 (ja) 2011-02-09
PT1707562E (pt) 2008-07-08
ES2308689T3 (es) 2008-12-01
FR2882555B1 (fr) 2007-05-04
US20090318417A1 (en) 2009-12-24
DK1707562T3 (da) 2008-10-13
EP1707562B1 (fr) 2008-05-28
MY158129A (en) 2016-08-30
CO5770097A1 (es) 2007-06-29
UY29406A1 (es) 2006-07-31
DE602006001312D1 (de) 2008-07-10
IL173959A0 (en) 2006-07-05
UA86595C2 (ru) 2009-05-12
EP1707562A1 (fr) 2006-10-04
US20080153803A1 (en) 2008-06-26
AP2006003521A0 (en) 2006-02-28
SG125229A1 (en) 2006-09-29
SA06270040B1 (ar) 2010-03-23
CY1109010T1 (el) 2014-07-02
PL1707562T3 (pl) 2008-08-29
US7361650B2 (en) 2008-04-22
JO2515B1 (en) 2010-03-17
NO20060948L (no) 2006-08-29
HK1096659A1 (en) 2007-06-08
EA200600320A1 (ru) 2006-08-25
KR20060095499A (ko) 2006-08-31
PE20061142A1 (es) 2006-12-30
CU20060037A7 (es) 2008-06-30
SI1707562T1 (sl) 2008-10-31
ATE396974T1 (de) 2008-06-15
GEP20084467B (en) 2008-08-25
HRP20080406T3 (en) 2008-09-30
RS50598B (sr) 2010-05-07
KR100835447B1 (ko) 2008-06-09
FR2882555A1 (fr) 2006-09-01
HRP20080406T5 (en) 2008-11-30

Similar Documents

Publication Publication Date Title
AR052926A1 (es) Forma cristalina gama del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones que la contienen
AR056573A1 (es) Forma cristalina delta del clohidrato de ivabradina,un procedimiento para su preparacion,composiciones farmaceuticas que la contienen y usos en trastornos cardiovasculares.
AR056931A1 (es) Forma cristalina gamma d del clorhidrato de ivabradina, un procedimiento para su preparacion, composiciones farmaceuticas que la contienen, y usos en trastornos cardiovasculares
AR056572A1 (es) FORMA CRISTALINA ð DEL CLOHIDRATO DE IVABRADINA,UN PROCEDIMIENTO PARA SU PREPARACION,COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN Y USOS EN TRASTORNOS CARDIOVASCULARES.
HRP20080418T3 (en) Crystalline form beta-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it
AR057713A1 (es) Forma cristalina iii de la agomelatina, un procedimiento para su preparacion, y las composiciones farmaceuticas que la contienen
AR057714A1 (es) Nueva forma cristalina iv de la agomelatina, un procedimiento para su preparacion, y las composiciones farmaceuticas que la contienen
BRPI0600623A (pt) forma beta-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0814957B8 (pt) composto, agente farmacêutico, e, uso do composto
MX2008000141A (es) Moduladores de lxr basados en imidazol.
UA93531C2 (en) Novel hydrogen sulfate salt
BRPI0804994A2 (pt) forma cristalina vi de agomelatina, um processo para a sua preparação e composições farmacêuticas contendo-a
EP1850180A4 (en) COMPOSITION FOR FORMING A LAYERING LINEOGRAPHY FILM CONTAINING A CARBOXYL PROTECTED COMPOSITION
MY151003A (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
TW200744588A (en) Pharmaceutical composition for external use
WO2007103839A3 (en) Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
RS53503B1 (en) AMORPHIC AND CRYSTAL FORM GENZ 112638 HEMITARTARATE AS A GLYCOSILKERAMIDE SYNTHASIS INHIBITOR
MX2009010515A (es) Antagonistas del receptor opioide periferico y usos de los mismos.
GB0621475D0 (en) Laser markable composition
BRPI0610343B8 (pt) composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo
WO2007074915A8 (en) Water-soluble benzoazepine compound and its pharmaceutical composition
WO2009063990A1 (ja) ベンズアゼピノン化合物
BRPI0607404A2 (pt) compostos de cinolina e seu uso como moduladores de receptor de x hepático
CU23927B1 (es) Sal de difumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamoilmetil)piperidin-4-il]oxi}quinazolina
SI1845780T1 (sl) Uporaba derivatov metilfenidata

Legal Events

Date Code Title Description
FC Refusal